This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Mednax Inc. (MD): Today's Featured Health Care Loser

Mednax ( MD) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 0.9%. By the end of trading, Mednax fell 42 cents (-0.6%) to $65.38 on heavy volume. Throughout the day, 538,940 shares of Mednax exchanged hands as compared to its average daily volume of 338,400 shares. The stock ranged in price between $64.64-$65.76 after having opened the day at $65.41 as compared to the previous trading day's close of $65.80. Other company's within the Health Care sector that declined today were: PetMed Express ( PETS), down 19.6%, NeurogesX ( NGSX), down 13.3%, Prima Biomed Ltd. ADR ( PBMD), down 11.5%, and Amyris ( AMRS), down 9.5%.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, maternal-fetal, other pediatric subspecialties, and anesthesia physician services in the United States and Puerto Rico. Mednax has a market cap of $3.3 billion and is part of the health services industry. The company has a P/E ratio of 14.6, below the average health services industry P/E ratio of 15 and below the S&P 500 P/E ratio of 17.7. Shares are down 8.6% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Mednax a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Vertex Pharmaceuticals ( VRTX), up 55.4%, Insmed ( INSM), up 51.9%, Escalon Medical Corporation ( ESMC), up 33.3%, and Graymark Healthcare ( GRMH), up 28.2%, were all gainers within the health care sector with GlaxoSmithKline ( GSK) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs